BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

949 related articles for article (PubMed ID: 33894490)

  • 21. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability.
    Ihmaid SK; Alraqa SY; Aouad MR; Aljuhani A; Elbadawy HM; Salama SA; Rezki N; Ahmed HEA
    Bioorg Chem; 2021 Jun; 111():104835. PubMed ID: 33798850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity.
    Pingaew R; Mandi P; Nantasenamat C; Prachayasittikul S; Ruchirawat S; Prachayasittikul V
    Eur J Med Chem; 2014 Jun; 81():192-203. PubMed ID: 24836071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents.
    El-Naggar AM; Abou-El-Regal MM; El-Metwally SA; Sherbiny FF; Eissa IH
    Mol Divers; 2017 Nov; 21(4):967-983. PubMed ID: 28815411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
    El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
    Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New 1,2,3-Triazole-Containing Hybrids as Antitumor Candidates: Design, Click Reaction Synthesis, DFT Calculations, and Molecular Docking Study.
    El Azab IH; El-Sheshtawy HS; Bakr RB; Elkanzi NAA
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33573040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies.
    Turky A; Sherbiny FF; Bayoumi AH; Ahmed HEA; Abulkhair HS
    Arch Pharm (Weinheim); 2020 Dec; 353(12):e2000170. PubMed ID: 32893368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, in vitro Antiproliferative Activity, Binding Modeling of 1,2,4,-Triazoles as New Anti-Breast Cancer Agents.
    Genc M; Karagoz Genc Z; Tekin S; Sandal S; Sirajuddin M; Hadda Taibi B; Sekerci M
    Acta Chim Slov; 2016 Dec; 63(4):726-737. PubMed ID: 28004087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
    Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
    Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
    Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity.
    El-Shershaby MH; Ghiaty A; Bayoumi AH; Al-Karmalawy AA; Husseiny EM; El-Zoghbi MS; Abulkhair HS
    Bioorg Med Chem; 2021 Jul; 42():116266. PubMed ID: 34126285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of 1,2,3-triazole linked aminocombretastatin conjugates as mitochondrial mediated apoptosis inducers.
    Kamal A; Shaik B; Nayak VL; Nagaraju B; Kapure JS; Shaheer Malik M; Shaik TB; Prasad B
    Bioorg Med Chem; 2014 Oct; 22(19):5155-67. PubMed ID: 25192811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiazolidinone-linked1,2,3-triazoles with monoterpenic skeleton as new potential anticancer agents: Design, synthesis and molecular docking studies.
    Oubella A; El Mansouri AE; Fawzi M; Bimoussa A; Laamari Y; Auhmani A; Morjani H; Robert A; Riahi A; Youssef Ait Itto M
    Bioorg Chem; 2021 Oct; 115():105184. PubMed ID: 34333421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of New Benzimidazole-1,2,3-triazole Hybrids as Tyrosinase Inhibitors.
    Mahdavi M; Ashtari A; Khoshneviszadeh M; Ranjbar S; Dehghani A; Akbarzadeh T; Larijani B; Khoshneviszadeh M; Saeedi M
    Chem Biodivers; 2018 Jul; 15(7):e1800120. PubMed ID: 29766648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of morpholines linked coumarin-triazole hybrids as anticancer agents.
    Goud NS; Pooladanda V; Mahammad GS; Jakkula P; Gatreddi S; Qureshi IA; Alvala R; Godugu C; Alvala M
    Chem Biol Drug Des; 2019 Sep; 94(5):1919-1929. PubMed ID: 31169963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
    Yang M; Liu H; Zhang Y; Wang X; Xu Z
    Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
    A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
    Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs.
    Vosooghi M; Firoozpour L; Rodaki A; Pordeli M; Safavi M; Ardestani SK; Dadgar A; Asadipour A; Moshafi MH; Foroumadi A
    Daru; 2014 Dec; 22(1):83. PubMed ID: 25539909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
    Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.